Recruiting NCT05907681
Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Breast Cancer, Metastatic Breast Cancer, Radiation Therapy Complication. Basic parameters: 19 years — 100 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study is a prospective observational study on outcomes of high precision hypo-fractionated radiotherapy in breast cancer with distant metastasis.
Primary outcome measures
- Local control rate [Time frame: 1-year]
Secondary outcome measures (3)
- Overall survival rate [Time frame: 1-year]
- Disease-free survival [Time frame: 1-year]
- Treatment-related toxicities [Time frame: 1-year]
Eligibility criteria
Inclusion criteria
- histologically confirmed breast cancer
- presence of distant metastasis
- radiation therapy using IMRT, SBRT, or proton therapy is done or planned
- Able and willing to comply with the study protocol
Exclusion criteria
- unable to adhere to the study protocol
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
South Korea · 1 center
- Samsung Medical Center — Seoul
Identifiers
NCT: NCT05907681 · 2023-04-032-003